Previous 10 | Next 10 |
home / stock / okyo / okyo articles
LONDON and NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing...
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news. AbbVie Inc. (NYSE: ABBV) an...
Shares of Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) rose sharply in today’s pre-market trading following fourth-quarter results. Salariu...
-Phase 2 OK-101 efficacy data to be released March 22nd, 2024- -KOL Event to be held on April 9th, 2024 at 12 PM ET- LONDON and NEW YORK, March 2...
LONDON and NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing ...
Gainers Orchard Therapeutics plc (NASDAQ: ORTX) shares climbed 97.7% to $15.98 after the company agreed to be acquired by Japan's Kyowa Kirin...
OKYO Pharma Limited (NASDAQ: OKYO) announced that its first drug candidate, OK-101, presently in a 240-patient phase 2 trial in patients with ...
Over the past twenty days of trading, OKYO Pharma Limited (NASDAQ: OKYO), from September 06, 2023 to October 03, 2023 there is a potential Short S...
Gainers SCWorx Corp. (NASDAQ: WORX) shares jumped 111% to $0.4000. Avinger, Inc. (NASDAQ: AVGR) surged 63.2% to $6.75 amid the company announcing...
News, Short Squeeze, Breakout and More Instantly...
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024 OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain ...
Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye Disease (DED) trial Conjunctival staining and ocular pain represe...
--News Direct-- OKYO Pharma Ltd CEO Gary Jacobs joined Steve Darling from Proactive to share additional key findings from the Phase 2 clinical trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED). This trial involved 240 pat...